-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

Benzinga·08/06/2026 19:52:35
Listen to the news
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.